FMS-like tyrosine kinase 3 (FLT3)-inhibition in FLT3 mutated acute myeloid leukemia: A promising approach
Acute myeloid leukemia (AML) represents a group of hematopoietic stem cell malignancies that affect approximately two to three adults per 100,000 each year in Western countries. Outcomes for the majority of patients remain poor. Cytogenetic aberrations represent one of the most important independent prognostic factors in AML. Over the past decade, significant progress has been made in the understanding of the cytogenetic and molecular determinants of AML pathogenesis. This has allowed development of risk-stratified treatment options in order to offer more adapted treatment options to patients at high risk.